FOLH1 and prostate carcinoma: This emergence can be attributed mainly to the success of DOTATOC- and DOTATATE-based theranostics in the case of neuroendocrine tumors and to prostate-specific membrane antigen (PSMA)–targeted inhibitors in the case of prostate cancer (1,2).